Veracyte, Inc. - Common Stock (VCYT)
24.06
+0.00 (0.00%)
NASDAQ · Last Trade: Nov 11th, 5:21 AM EST
News & Press Releases
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Veracyte (VCYT)
Veracyte's third-quarter report said Decipher Prostate volume came in below the Company's expectations, and full-year 2026 revenue guidance was narrowed as Decipher’s annual volume projections were slashed. The investigation concerns potential securities law violations tied to Decipher Prostate growth risk
By Levi & Korsinsky, LLP · Via GlobeNewswire · November 10, 2026
VCYT Investors Have Opportunity to Join Veracyte, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Veracyte, Inc. (“Veracyte” or “the Company”) (NASDAQ: VCYT) for violations of the securities laws.
By Schall, Brown & Schwartz LLP · Via Business Wire · November 9, 2026
VCYT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Veracyte (VCYT)
NEW YORK CITY, NY / ACCESS Newswire / November 9, 2026 / VCYT shareholders are absorbing losses after Veracyte (NASDAQ:VCYT) lowered the top of its full-year 2026 revenue guidance to $593 million from $596 million on November 4, 2026. The new ceiling sits below a cited analyst estimate of $593.9 million, and the shares fell as the market reacted to a weaker outlook for the Company's Decipher Prostate test. If you lost money on Veracyte stock, you have the right to have those losses evaluated at no cost to you. Shareholders who suffered losses are encouraged to request a free review of their VCYT losses. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
By Levi & Korsinsky, LLP · Via ACCESS Newswire · November 9, 2026
Veracyte (NASDAQ:VCYT): An Undervalued Value Stock With Quality Fundamentalschartmill.com
Via Chartmill · November 9, 2026
Veracyte (NASDAQ:VCYT): Affordable Growth Backed by Strong Fundamentalschartmill.com
Via Chartmill · October 13, 2026
Veracyte (NASDAQ:VCYT) Offers Affordable Growth Backed by Strong Health and Cash Flowchartmill.com
Via Chartmill · September 21, 2026
VCYT Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud Against Veracyte, Inc.
VCYT’s stock is down more than 50%; Ademi LLP is investigating Veracyte for potential securities fraud.
By Ademi LLP · Via GlobeNewswire · November 5, 2026
Veracyte (VCYT) Q3 2026 Earnings Call Transcriptfool.com
Decipher volume fell short as Veracyte closed a $150M deal.
Via The Motley Fool · November 5, 2026
Top Gainers and Losers: Nov. 5 Low-Priced Market Moverschartmill.com
Via Chartmill · November 5, 2026
Today's US Session: Top Stock Gainers and Loserschartmill.com
Via Chartmill · November 5, 2026
Notable Gap Movers on Nov. 5, 2026: AEHL and ZNB Gap Higher; VCYT and MNTN Gap Lowerchartmill.com
Via Chartmill · November 5, 2026
Premarket Movers: Gainers and Decliners on Nov. 5, 2026chartmill.com
Via Chartmill · November 5, 2026
What Veracyte (VCYT) Said on Its Q3 Earnings Callmarketbeat.com
Veracyte (NASDAQ:VCYT) reported 15% revenue growth for the third quarter of 2026, but lowered its near-term expectations for its Decipher Prostate test after volume came in below management’s forecast. The company also outlined a preliminary 2027 outlook for mid-single-digit revenue growth as it inv
Via MarketBeat · November 5, 2026
After-Hours Market Movers: Nov. 4, 2026 Gainers and Loserschartmill.com
Via Chartmill · November 4, 2026
Veracyte Announces Third Quarter 2026 Financial Results
Grew total revenue to $151.8 million and testing revenue to $146.4 million, representing 15% year-over-year growth Announces $100 million share repurchase program
By Veracyte, Inc. · Via GlobeNewswire · November 4, 2026
Ten Afirma Abstracts to Highlight Thyroid Nodule Diagnosis and Cancer Research at ATA 2026
Two oral presentations mark Afirma’s strongest podium presence in recent years, alongside eight posters
By Veracyte, Inc. · Via GlobeNewswire · November 2, 2026
Veracyte to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it will be participating in the following investor conferences:
By Veracyte, Inc. · Via GlobeNewswire · October 29, 2026
Phase III Trial Shows Veracyte’s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer
STAMPEDE study analysis providing new predictive evidence in clinically very high-risk, nonmetastatic disease to be presented at ESMO
By Veracyte, Inc. · Via GlobeNewswire · October 23, 2026
Six Studies to Highlight Veracyte’s Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026
Oral presentations include new Decipher treatment-selection evidence and an OPTIMA breast cancer health economic analysis
By Veracyte, Inc. · Via GlobeNewswire · October 19, 2026
Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test
Milestone supports broader U.S. adoption of Prosigna and expands access for eligible patients with early-stage breast cancer
By Veracyte, Inc. · Via GlobeNewswire · October 16, 2026
Veracyte to Release Third Quarter 2026 Financial Results on November 4, 2026
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter 2026 after the close of market on Wednesday, November 4, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
By Veracyte, Inc. · Via GlobeNewswire · October 14, 2026
Phase III Trial Demonstrates Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation
First predictive evidence in intermediate-risk prostate cancer supporting use of the Decipher test to guide short-term hormone therapy decisions to be presented at ASTRO 2026
By Veracyte, Inc. · Via GlobeNewswire · September 29, 2026
Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026
Six oral presentations and two posters will highlight Decipher’s prognostic and predictive value in identifying patients’ risk of progression and likelihood of benefiting from treatment intensification
By Veracyte, Inc. · Via GlobeNewswire · September 25, 2026
Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform
Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the patient journey
By Veracyte, Inc. · Via GlobeNewswire · September 14, 2026
Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 7:00 a.m. Eastern Time.
By Veracyte, Inc. · Via GlobeNewswire · September 1, 2026